Terms: = Kidney tumors AND Ki-67 AND Clinical Outcome
18 results:
1. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract] [Full Text] [Related]
2. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
[TBL] [Abstract] [Full Text] [Related]
3. Global levels of histone modifications predict prognosis in different cancers.
Seligson DB; Horvath S; McBrian MA; Mah V; Yu H; Tze S; Wang Q; Chia D; Goodglick L; Kurdistani SK
Am J Pathol; 2009 May; 174(5):1619-28. PubMed ID: 19349354
[TBL] [Abstract] [Full Text] [Related]
4. outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype.
Delahunt B; Bethwaite PB; Nacey JN
Pathology; 2007 Oct; 39(5):459-65. PubMed ID: 17886093
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic biomarkers in renal cell carcinoma: relevance of DNA ploidy in predicting disease-related survival.
Pinto AE; Monteiro P; Silva G; Ayres JV; Soares J
Int J Biol Markers; 2005; 20(4):249-56. PubMed ID: 16398407
[TBL] [Abstract] [Full Text] [Related]
6. Immunohistochemical analysis of tumor polyamines discriminates high-risk patients undergoing nephrectomy for renal cell carcinoma.
Rioux-Leclercq N; Delcros JG; Bansard JY; Epstein JI; Patard JJ; Lobel B; Guillé F; Jouan F; Bellaud P; Moulinoux JP
Hum Pathol; 2004 Oct; 35(10):1279-84. PubMed ID: 15492997
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic value of the expression of ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma.
Yildiz E; Gokce G; Kilicarslan H; Ayan S; Goze OF; Gultekin EY
BJU Int; 2004 May; 93(7):1087-93. PubMed ID: 15142169
[TBL] [Abstract] [Full Text] [Related]
8. Correlation of ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma.
Visapää H; Bui M; Huang Y; Seligson D; Tsai H; Pantuck A; Figlin R; Rao JY; Belldegrun A; Horvath S; Palotie A
Urology; 2003 Apr; 61(4):845-50. PubMed ID: 12670587
[TBL] [Abstract] [Full Text] [Related]
9. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.
Schraml P; Struckmann K; Hatz F; Sonnet S; Kully C; Gasser T; Sauter G; Mihatsch MJ; Moch H
J Pathol; 2002 Feb; 196(2):186-93. PubMed ID: 11793370
[TBL] [Abstract] [Full Text] [Related]
10. clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma.
Rioux-Leclercq N; Epstein JI; Bansard JY; Turlin B; Patard JJ; Manunta A; Chan T; Ramee MP; Lobel B; Moulinoux JP
Hum Pathol; 2001 Nov; 32(11):1209-15. PubMed ID: 11727260
[TBL] [Abstract] [Full Text] [Related]
11. Extrapleural solitary fibrous tumor: clinicopathologic study of 17 cases and molecular analysis of the p53 pathway.
Morimitsu Y; Nakajima M; Hisaoka M; Hashimoto H
APMIS; 2000 Sep; 108(9):617-25. PubMed ID: 11110050
[TBL] [Abstract] [Full Text] [Related]
12. Value of immunohistochemical ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma.
Rioux-Leclercq N; Turlin B; Bansard J; Patard J; Manunta A; Moulinoux JP; Guillé F; Ramée MP; Lobel B
Urology; 2000 Apr; 55(4):501-5. PubMed ID: 10736491
[TBL] [Abstract] [Full Text] [Related]
13. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Syrjänen K; Kosma VM
Br J Cancer; 1999 Aug; 80(12):2001-7. PubMed ID: 10471053
[TBL] [Abstract] [Full Text] [Related]
14. clinical outcome in localized renal cell carcinomas related to immunoexpression of proliferating cell nuclear antigen, ki-67 antigen, and tumor size.
Onda H; Yasuda M; Serizawa A; Osamura RY; Kawamura N
Oncol Rep; 1999; 6(5):1039-43. PubMed ID: 10425300
[TBL] [Abstract] [Full Text] [Related]
15. Nephrogenic adenoma in renal transplant recipients: a truly benign lesion?
Pycha A; Mian C; Reiter WJ; Brössner C; Haitel A; Wiener H; Maier U; Marberger M
Urology; 1998 Nov; 52(5):756-61. PubMed ID: 9801094
[TBL] [Abstract] [Full Text] [Related]
16. Proliferating cell nuclear antigen and MIB-1. An alternative to classic prognostic indicators in renal cell carcinomas?
Haitel A; Wiener HG; Migschitz B; Marberger M; Susani M
Am J Clin Pathol; 1997 Feb; 107(2):229-35. PubMed ID: 9024073
[TBL] [Abstract] [Full Text] [Related]
17. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal ki-67 antibody labeling. Correlation with clinical outcome.
Delahunt B; Bethwaite PB; Thornton A; Ribas JL
Cancer; 1995 Jun; 75(11):2714-9. PubMed ID: 7743475
[TBL] [Abstract] [Full Text] [Related]
18. [In situ determination of the ki-67 growth fraction (ki-67 GF) in human tumors (studies in breast cancer)].
Lellé RJ
Acta Histochem Suppl; 1990; 39():109-24. PubMed ID: 2080254
[TBL] [Abstract] [Full Text] [Related]
